Modality
ERT
MOA
MALT1i
Target
USP1
Pathway
Neuroinflam
Gastric CaCervical CaCTCL
Development Pipeline
Preclinical
~Nov 2014
→ ~Feb 2016
Phase 1
~May 2016
→ ~Aug 2017
Phase 2
Nov 2017
→ Sep 2029
Phase 2Current
NCT08521157
1,863 pts·CTCL
2017-11→2029-09·Not yet recruiting
1,863 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-224mo agoNDA· CTCL
2029-09-033.4y awayPh2 Data· CTCL
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P2
Not yet…
Catalysts
NDA
2025-11-22 · 4mo ago
CTCL
Ph2 Data
2029-09-03 · 3.4y away
CTCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08521157 | Phase 2 | CTCL | Not yet recr... | 1863 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C | |
| Gelisertib | Samsung Biologics | Approved | IL-23 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A |